Abstract：
We aimed to determine the level of miRNAs 16 and 135a in lifelong premature ejaculation (LPE) patients versus controls. Moreover, we evaluated the potential interplay between the studied miRNAs and fluoxetine in these patients after utilizing fluoxetine daily for 3 months. The study involved 60 consecutive LPE patients and 20 healthy age matched individuals as controls. The median miRNA16 was significantly higher in the controls (1.02) compared to the patients (0.31) (p < 0.001). Moreover, the median miRNA-135a was significantly higher in the controls compared to the patients 1.02 and 0.35, p < 0.001, respectively. In addition, the median pre-treatment miRNA16 in the responders was 0.29 that significantly increased to 0.66 (p < 0.001). The median pre-treatment miRNA-135a in the responders was 0.27 that significantly increased to 0.65 (p < 0.001). Furthermore, considering EXP(β) for the odds ratio evaluation, with a 95% degree of confidence, a 1 fold increase in pre-treatment miRNA 135a fold change decreases the odds for being responsive to SSRI by 0.028. Meanwhile, there was non-significant association between fluoxetine responsiveness and age, pre-treatment miRNA 16, pre-treatment PEDT and pre-treatment IELT. The current study had shown that a lower pre-treatment miRNA 135a was significantly associated with response to fluoxetine.
摘要：
我们旨在确定终身早泄（LPE）患者与对照组中miRNA16和135a的水平。此外，我们评估了这些患者在每天使用氟西汀3个月后所研究的miRNA和氟西汀之间的潜在相互作用.该研究涉及60名连续的LPE患者和20名健康年龄匹配的个体作为对照。与患者(0.31)相比,对照(1.02)中的miRNA16中位数显著更高(p<0.001)。此外，在对照组中,miRNA-135a的中位数显著高于患者1.02和0.35,p<0.001.此外,应答者治疗前miRNA16的中位数为0.29,显著增加至0.66(p<0.001).应答者中的中位治疗前miRNA-135a为0.27,显著增加至0.65(p<0.001)。此外，考虑EXP(β)的比值比评估，95%的置信度,治疗前miRNA135a倍数变化增加1倍,对SSRI应答的几率降低0.028.同时,氟西汀反应性与年龄之间无显著关联，预处理miRNA16、预处理PEDT和预处理IELT。目前的研究表明，较低的预处理miRNA135a与对氟西汀的反应显着相关。
